Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
|ClinicalTrials.gov Identifier: NCT00897754|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 19, 2017
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.
PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.
|Condition or disease||Intervention/treatment|
|Colorectal Cancer||Genetic: gene expression analysis Genetic: protein expression analysis Genetic: reverse transcriptase-polymerase chain reaction Other: immunoenzyme technique Other: immunohistochemistry staining method Other: immunologic technique|
- Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy.
OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy|
|Actual Study Start Date :||July 24, 2007|
|Primary Completion Date :||February 1, 2009|
|Study Completion Date :||February 1, 2009|
- Mean scores for VEGFb and pan-VEGF gene expression by IHC [ Time Frame: 1 month ]
- Gene expression as measured by tissue microarrays [ Time Frame: 1 month ]
- Splice form expression as measured by reverse transcriptase-PCR [ Time Frame: 1 month ]
- VEGF165b protein expression as measured by ELISA [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00897754
|Study Chair:||David Bates, PhD||Bristol Heart Institute at University of Bristol|